BR112022004699A2 - Vs-6063 em combinação com ch5126766 para o tratamento de câncer - Google Patents

Vs-6063 em combinação com ch5126766 para o tratamento de câncer

Info

Publication number
BR112022004699A2
BR112022004699A2 BR112022004699A BR112022004699A BR112022004699A2 BR 112022004699 A2 BR112022004699 A2 BR 112022004699A2 BR 112022004699 A BR112022004699 A BR 112022004699A BR 112022004699 A BR112022004699 A BR 112022004699A BR 112022004699 A2 BR112022004699 A2 BR 112022004699A2
Authority
BR
Brazil
Prior art keywords
combination
cancer treatment
cancer
treatment
inhibitor
Prior art date
Application number
BR112022004699A
Other languages
English (en)
Inventor
Udai Banerji
Original Assignee
The Institute Of Cancer Res Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institute Of Cancer Res Royal Cancer Hospital filed Critical The Institute Of Cancer Res Royal Cancer Hospital
Publication of BR112022004699A2 publication Critical patent/BR112022004699A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

vs-6063 em combinação com ch5126766 para o tratamento de câncer. essa invenção está relacionada aos métodos que compreendem a administração de um inibidor de fak (por exemplo, vs-6063) em combinação com um inibidor duplo de raf/mek (por exemplo, ch5126766) que são úteis no tratamento de crescimento celular anormal, por exemplo, câncer, em um indivíduo como, por exemplo, humanos.
BR112022004699A 2019-09-13 2020-09-11 Vs-6063 em combinação com ch5126766 para o tratamento de câncer BR112022004699A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/074565 WO2021047783A1 (en) 2019-09-13 2019-09-13 Vs-6063 in combination with ch5126766 for the treatment of cancer
PCT/EP2020/075455 WO2021048339A1 (en) 2019-09-13 2020-09-11 Vs-6063 in combination with ch5126766 for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112022004699A2 true BR112022004699A2 (pt) 2022-06-14

Family

ID=67988988

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004699A BR112022004699A2 (pt) 2019-09-13 2020-09-11 Vs-6063 em combinação com ch5126766 para o tratamento de câncer

Country Status (11)

Country Link
US (2) US11517573B2 (pt)
EP (1) EP4028010A1 (pt)
JP (2) JP2022547358A (pt)
KR (1) KR20220078606A (pt)
CN (1) CN114630667A (pt)
AU (1) AU2020344829A1 (pt)
BR (1) BR112022004699A2 (pt)
CA (1) CA3152805A1 (pt)
MX (1) MX2022003063A (pt)
TW (1) TW202114677A (pt)
WO (3) WO2021047783A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4062914A4 (en) * 2019-11-18 2024-01-17 Inxmed Nanjing Co Ltd USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION
MX2023000589A (es) * 2020-07-13 2023-02-13 Verastem Inc Terapia de combinacion para tratar el crecimiento celular anormal.
WO2023009572A1 (en) * 2021-07-27 2023-02-02 Verastem, Inc. Combination therapy for treating abnormal cell growth
CA3235499A1 (en) * 2021-10-28 2023-05-04 Verastem, Inc. Combination therapy for treating abnormal cell growth
CA3236424A1 (en) * 2021-11-02 2023-05-11 Verastem, Inc. Methods of treating abnormal cell growth
WO2023138630A1 (zh) * 2022-01-21 2023-07-27 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN114917232A (zh) * 2022-06-27 2022-08-19 厦门骨本生物科技有限公司 Ch5126766在制备缓解或治疗动物骨关节炎的药物中的应用
CN115177622A (zh) * 2022-07-19 2022-10-14 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
ES2593486T3 (es) 2007-04-18 2016-12-09 Pfizer Products Inc. Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
EP2172198B1 (en) 2007-07-20 2014-04-16 Chugai Seiyaku Kabushiki Kaisha p27 PROTEIN INDUCER
BR112012008483A2 (pt) 2009-10-12 2019-09-24 Hoffmann La Roche combunações de um inibidor de pi3k e um inibidor de mex
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AR084216A1 (es) 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
WO2013035754A1 (ja) 2011-09-05 2013-03-14 中外製薬株式会社 クマリン誘導体の製造方法
US20150071918A1 (en) 2012-05-09 2015-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptides for the treatment of cancer
KR101909801B1 (ko) 2012-06-08 2018-10-18 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
EP2906215A4 (en) 2012-10-12 2016-05-18 SUITS
BR112016016021B1 (pt) 2014-01-09 2023-01-10 Verastem, Inc. Composição farmacêutica, seu uso, formulação de dosagem oral e método para preparar comprimido por compressão direta em formulação de dosagem única
ES2945387T3 (es) 2014-02-07 2023-06-30 Verastem Inc Procedimientos y composiciones para tratar el crecimiento celular anormal
MX2018000288A (es) 2015-06-29 2018-11-09 Verastem Inc Composiciones terapeuticas, combinaciones y metodos de uso.
SG11202001282UA (en) * 2017-09-07 2020-03-30 Revolution Medicines Inc Shp2 inhibitor compositions and methods for treating cancer
WO2019096397A1 (en) 2017-11-16 2019-05-23 The Institute Of Cancer Research: Royal Cancer Hospital Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder

Also Published As

Publication number Publication date
CN114630667A (zh) 2022-06-14
WO2021048339A1 (en) 2021-03-18
WO2021047783A1 (en) 2021-03-18
AU2020344829A1 (en) 2022-03-03
US20230277535A1 (en) 2023-09-07
TW202114677A (zh) 2021-04-16
WO2021047798A1 (en) 2021-03-18
JP2022547358A (ja) 2022-11-14
US20220031698A1 (en) 2022-02-03
KR20220078606A (ko) 2022-06-10
EP4028010A1 (en) 2022-07-20
CA3152805A1 (en) 2021-03-18
US11517573B2 (en) 2022-12-06
MX2022003063A (es) 2022-06-14
JP2022172480A (ja) 2022-11-17

Similar Documents

Publication Publication Date Title
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CO2018006590A2 (es) Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1
BR112018070161A2 (pt) moduladores de receptores de estrogênio
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
BR112016029318A2 (pt) tratamento de mielomas
BR112016026950A2 (pt) composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas
CR20140422A (es) Composiciones de enzima digestiva estable
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
EA201792509A1 (ru) Лечение рака
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
BR112018077358A2 (pt) tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
WO2018039475A8 (en) Use of pridopidine for treating dystonias
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
BR112017008496A2 (pt) compostos para uso em tratamento antelmíntico
BR112021022951A2 (pt) Composições e métodos para o tratamento de doenças mediadas por atpase
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112017020513A2 (pt) método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe
BR112019005886A2 (pt) tratamento com água de material lipídico
BR112018017077A2 (pt) terapias de combinação para tratamento de atrofia muscular espinhal